The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
Open Access
- 26 November 2015
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (2) , 235-240
Abstract
Mantle Cell Lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic regimens are active in this disease there is no established gold standard therapy. Rituximab has been used widely in B cell malignancies with good effect but there is no evidence that it improves outcomes when added to chemotherapy in this disease. We performed a randomized, open-label, multicenter study looking at the addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide in patients with newly diagnosed mantle cell lymphoma. A total of 370 patients were randomized. With a median follow up of 6 years, rituximab improved the median progression-free survival from 14.9 to 29.8 months (p<0.001) and overall survival from 37.0 to 44.5 months (p=0.005). This equates to absolute differences of 9.0% and 22.1% for overall and progression free survival respectively at 2 years. Overall response rates were similar but complete response rates were significantly higher in the rituximab arm 52.7% vs. 39.9% (p = 0.014). There was no clinically significant additional toxicity observed with the addition of Rituximab. Overall, approximately 18% of patients died of non-lymphomatous causes, most commonly infections. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy significantly improves outcomes in patients with mantle cell lymphoma. However these regimens have significant late toxicity and should be used with caution. This trial is registered (ISRCTN81133184 and ClinicalTrials.gov NCT00641095) and supported by the UK National Cancer Research Network.Keywords
This publication has 25 references indexed in Scilit:
- Treatment of Older Patients with Mantle-Cell LymphomaNew England Journal of Medicine, 2012
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular LymphomaJournal of Clinical Oncology, 2008
- Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaCochrane Database of Systematic Reviews, 2007
- Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialThe Lancet, 2007
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Journal of Clinical Oncology, 2005
- Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free SurvivalJournal of Clinical Oncology, 2002
- Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell LymphomaLeukemia & Lymphoma, 2001
- New anti-cancer therapies, new opportunities for infectionCurrent Opinion in Infectious Diseases, 1999
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999